6.
Collins L, Toulouse A, Connor T, Nolan Y
. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology. 2012; 62(7):2154-68.
DOI: 10.1016/j.neuropharm.2012.01.028.
View
7.
Davie C
. A review of Parkinson's disease. Br Med Bull. 2008; 86:109-27.
DOI: 10.1093/bmb/ldn013.
View
8.
Appel S, Beers D, Henkel J
. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2009; 31(1):7-17.
PMC: 4126423.
DOI: 10.1016/j.it.2009.09.003.
View
9.
Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R
. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflammation. 2018; 15(1):205.
PMC: 6044047.
DOI: 10.1186/s12974-018-1248-8.
View
10.
Jiang T, Li G, Xu J, Gao S, Chen X
. The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?. Front Immunol. 2018; 9:2047.
PMC: 6170625.
DOI: 10.3389/fimmu.2018.02047.
View
11.
Korin B, Ben-Shaanan T, Schiller M, Dubovik T, Azulay-Debby H, Boshnak N
. High-dimensional, single-cell characterization of the brain's immune compartment. Nat Neurosci. 2017; 20(9):1300-1309.
DOI: 10.1038/nn.4610.
View
12.
Zhang Y, Feng S, Nie K, Li Y, Gao Y, Gan R
. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochem Biophys Res Commun. 2018; 499(4):797-802.
DOI: 10.1016/j.bbrc.2018.03.226.
View
13.
Jiang S, Gao H, Luo Q, Wang P, Yang X
. The correlation of lymphocyte subsets, natural killer cell, and Parkinson's disease: a meta-analysis. Neurol Sci. 2017; 38(8):1373-1380.
DOI: 10.1007/s10072-017-2988-4.
View
14.
Caggiu E, Paulus K, Galleri G, Arru G, Manetti R, Sechi G
. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease. J Neuroimmunol. 2017; 310:26-31.
DOI: 10.1016/j.jneuroim.2017.06.004.
View
15.
. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602.
PMC: 5055577.
DOI: 10.1016/S0140-6736(16)31678-6.
View
16.
Harms A, Cao S, Rowse A, Thome A, Li X, Mangieri L
. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013; 33(23):9592-600.
PMC: 3903980.
DOI: 10.1523/JNEUROSCI.5610-12.2013.
View
17.
Baba Y, Kuroiwa A, Uitti R, Wszolek Z, Yamada T
. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005; 11(8):493-8.
DOI: 10.1016/j.parkreldis.2005.07.005.
View
18.
Cancela J, Pastorino M, Arredondo M, Nikita K, Villagra F, Pastor M
. Feasibility study of a wearable system based on a wireless body area network for gait assessment in Parkinson's disease patients. Sensors (Basel). 2014; 14(3):4618-33.
PMC: 4003960.
DOI: 10.3390/s140304618.
View
19.
Gruden M, Sewell R, Yanamandra K, Davidova T, Kucheryanu V, Bocharov E
. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol. 2011; 233(1-2):221-7.
DOI: 10.1016/j.jneuroim.2010.12.001.
View
20.
Bokor M, Farago A, Garam T, Malatinszky G, Schnabel R
. Antibody-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease. J Neurol Sci. 1993; 115(1):47-50.
DOI: 10.1016/0022-510x(93)90065-7.
View